Zobrazeno 1 - 10
of 60
pro vyhledávání: '"David G. Motto"'
Autor:
X. Long Zheng, Michelle Thiboutot, Douglas B. Cines, Mortimer Poncz, Khalil Bdeir, David G. Motto, Lenka Yunk, Stephen Kacir, Eric M. Ostertag, Vincent Hayes, Don L. Siegel, Gayathri Gulendran
Publikováno v:
Transfusion. 56:1775-1785
BACKGROUND Acquired thrombotic thrombocytopenic purpura (TTP) is a potentially fatal disease in which ultralarge von Willebrand factor (UL-VWF) multimers accumulate as a result of autoantibody inhibition of the VWF protease, ADAMTS13. Current treatme
Publikováno v:
Blood. 121:3733-3741
Application of ferric chloride (FeCl(3)) to exposed blood vessels is widely used to initiate thrombosis in laboratory mice. Because the mechanisms by which FeCl(3) induces endothelial injury and subsequent thrombus formation are little understood, we
Publikováno v:
Free Radical Biology and Medicine. 56:17-27
Heme synthesis partially occurs in the mitochondrial matrix, thus there is a high probability that enzymes and intermediates important in the production of heme will be exposed to metabolic byproducts including reactive oxygen species. In addition, t
Publikováno v:
Blood. 120:5224-5230
Abstract 264 Background and objective: ADAMTS13 (A Disintegrin And Metalloprotease with Thrombospondin type I repeats-13) cleaves von Willebrand factor (VWF), a large multimeric protein that plays an important role in thrombus formation by binding to
Autor:
A. Kopić, M. Le Besnerais, Julie Favre, Lionel Nicol, Paul Mulder, Jérémie Martinet, David G. Motto, Paul Coppo, Ygal Benhamou, Agnès Veyradier, Hervé Levesque, Cécile V. Denis, Vincent Richard
Publikováno v:
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, Wiley, 2016, 14 (10), pp.1917-1930. ⟨10.1111/jth.13439⟩
Journal of Thrombosis and Haemostasis, Wiley, 2016, 14 (10), pp.1917-1930. ⟨10.1111/jth.13439⟩
Background Thrombotic thrombocytopenic purpura (TTP) is a life-threatening illness caused by deficiency of the Von Willebrand factor (VWF) cleaving protease ADAMTS13. Endothelial injury is believed to be a key initiating event in the pathogenesis lea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd7ca432c7e438f2b95e72ed58b2ee3f
https://www.hal.inserm.fr/inserm-02296620
https://www.hal.inserm.fr/inserm-02296620
Autor:
Eric M, Ostertag, Khalil, Bdeir, Stephen, Kacir, Michelle, Thiboutot, Gayathri, Gulendran, Lenka, Yunk, Vincent M, Hayes, David G, Motto, Mortimer, Poncz, X Long, Zheng, Douglas B, Cines, Don L, Siegel
Acquired thrombotic thrombocytopenic purpura (TTP) is a potentially fatal disease in which ultralarge von Willebrand factor (UL-VWF) multimers accumulate as a result of autoantibody inhibition of the VWF protease, ADAMTS13. Current treatment is not s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ea4ef28116972866b8015b71ae6bbafb
https://europepmc.org/articles/PMC4938757/
https://europepmc.org/articles/PMC4938757/
Publikováno v:
Journal of Thrombosis and Haemostasis. 10:1665-1671
Summary. Background: ADAMTS13 cleaves hyperactive ultra-large von Willebrand factor (ULVWF) multimers into smaller and less active forms. It remains unknown whether VWF-mediated inflammatory processes play a role in the enhanced brain injury due to A
Autor:
David G. Motto, Neelam Chauhan, Mohammad Moshahid Khan, Chintan Gandhi, Jeff W. Stevens, Steven R. Lentz, Anil K. Chauhan
Publikováno v:
Stroke. 43:1376-1382
Background and Purpose— The fibronectin isoform containing the alternatively spliced extra domain A (EDA + -FN) is normally absent from the circulation, but plasma levels of EDA + -FN can become markedly elevated in several human pathological condi
Autor:
Bernhard Lämmle, Johanna A. Kremer Hovinga, Sara K. Vesely, Deirdra R. Terrell, David G. Motto, James N. George
Publikováno v:
Transfusion. 51:2237-2243
BACKGROUND It has been postulated that blood group O subjects may be partially protected against thrombotic thrombocytopenic purpura (TTP) because they have lower plasma levels of von Willebrand factor (VWF).
Autor:
David G. Motto, Nicolas Lerolle, Cécile V. Denis, I. Badirou, Dominique Baruch, Patrick Bruneval, C. Dunois-Lardé, Gary S. Hill, JL Diehl
Publikováno v:
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, Wiley, 2009, 7 (5), pp.843-850. ⟨10.1111/j.1538-7836.2009.03313.x⟩
Journal of Thrombosis and Haemostasis, 2009, 7 (5), pp.843-850. ⟨10.1111/j.1538-7836.2009.03313.x⟩
Journal of Thrombosis and Haemostasis, Wiley, 2009, 7 (5), pp.843-850. ⟨10.1111/j.1538-7836.2009.03313.x⟩
Journal of Thrombosis and Haemostasis, 2009, 7 (5), pp.843-850. ⟨10.1111/j.1538-7836.2009.03313.x⟩
International audience; Summary. Background: During sepsis, von Willebrand factor (VWF) is abundantly secreted; the main mechanism regulating its size involves specific proteolysis by the metalloprotease ADAMTS-13. Objectives: To determine whether AD